Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study (Q35030003)

5 August 2017

title

Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study (English)

1 reference

5 August 2017

1 reference

Keith A Hawkins

7

0 references

Ralitza Gueorguieva

object named as

Ralitza V Gueorguieva

8

0 references

Hal Morgenstern

2

object named as

Hal Morgenstern

1 reference

5 August 2017

Scott W Woods

1

1 reference

5 August 2017

John R Saksa

3

1 reference

5 August 2017

Barbara C Walsh

4

1 reference

5 August 2017

Michelle C Sullivan

5

1 reference

5 August 2017

Roy Money

6

1 reference

5 August 2017

William M Glazer

9

1 reference

5 August 2017

publication date

9 February 2010

1 reference

The Journal of Clinical Psychiatry

5 August 2017

published in

1 reference

5 August 2017

volume

71

1 reference

5 August 2017

issue

4

1 reference

5 August 2017

page(s)

463-474

1 reference

Does the degree of smoking effect the severity of tardive dyskinesia? A longitudinal clinical trial

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Neuroleptic Drug Exposure and Incidence of Tardive Dyskinesia: A Records-based Case-Control Study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Chlorpromazine equivalent doses for the newer atypical antipsychotics

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Distinguishing akathisia and tardive dyskinesia: a review of the literature

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

A tardive dyskinesia clinic in a mental health center

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Tardive dyskinesia: prevalence, incidence, and risk factors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Tremor and tardive dyskinesia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Recognition and differential diagnosis of tardive dyskinesia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Tardive Dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Neurological abnormalities in first-episode schizophrenia: temporal stability and clinical and outcome correlates

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Rate of tardive dyskinesia in hospitalized patients.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Focus on polypharmacy in schizophrenia: does anyone truly benefit?

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Polypharmacy in patients with schizophrenia.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Combination antipsychotic therapy in clinical practice.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Incidence and risk factors for severe tardive dyskinesia in older patients.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Incidence and correlates of tardive dyskinesia in first episode of schizophrenia.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Evidence that lithium protects against tardive dyskinesia: The Curaçao Extrapyramidal Syndromes study VI

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109728

Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

25 October 2018

1 reference

12 December 2020

Prospective study of tardive dyskinesia in the elderly: rates and risk factors

1 reference

12 December 2020

Cognitive impairment in tardive dyskinesia

1 reference

12 December 2020

Changes in negative symptoms and the risk of tardive dyskinesia: a longitudinal study. UK700 Group

1 reference

12 December 2020

1 reference

12 December 2020

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

1 reference

12 December 2020

Tardive dyskinesia circa 2006

1 reference

12 December 2020

Longitudinal analysis of abnormal involuntary movements in long-term clozapine-treated patients

1 reference

12 December 2020

Incidence of tardive dyskinesia: five-year data from a prospective study

1 reference

12 December 2020

Does clozapine cause tardive dyskinesia?

1 reference

12 December 2020

The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine

1 reference

12 December 2020

1 reference

12 December 2020

Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association

1 reference

12 December 2020

Predictors of tardive dyskinesia: results of a cross-sectional study in an outpatient population

1 reference

12 December 2020

Olanzapine and tardive dyskinesia

1 reference

12 December 2020

Research Diagnoses for Tardive Dyskinesia

1 reference

12 December 2020

The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients

1 reference

12 December 2020

Tardive dyskinesia may be only akathisia

1 reference

12 December 2020

Handedness and the risk of tardive dyskinesia

1 reference

12 December 2020

Identifiers

DOI

10.4088/JCP.07M03890YEL

1 reference

5 August 2017

1 reference

5 August 2017

1 reference